Aptiom

(Eslicarbazepine acetate)

Aptiom

Drug updated on 11/10/2023

Dosage FormTablet (oral; 200 mg, 400 mg, 600 mg, 800 mg)
Drug ClassAnticonvulsants
Ongoing and Completed StudiesClinicalTrials.gov

Indication

  • Indicated as adjunctive treatment of partial-onset seizures.

Product Monograph / Prescribing Information

Document TitleYearSource
Aptiom (eslicarbazepine acetate) Prescribing Information.2023Sunovion Pharmaceuticals Inc., Marlborough, MA

Systematic Reviews / Meta-Analyses

Document TitleYearSource
Initial monotherapy with eslicarbazepine acetate for the management of adult patients with focal epilepsy in clinical practice: a meta-analysis of observational studies.2023International Journal of Neuroscience
Antiepileptic drug monotherapy for epilepsy: a network meta‐analysis of individual participant data.2022Cochrane Database of Systematic Reviews
Third‑generation antiseizure medications for adjunctive treatment of focal‑onset seizures in adults: a systematic review and network meta‑analysis.2022Drugs
Adjunctive treatment with eslicarbazepine acetate for adults and children with focal-onset epilepsy: a meta-analysis.2022Frontiers in Neurology
Comparative antiseizure medications of adjunctive treatment for children with drug-resistant focal-onset seizures: A systematic review and network meta-analysis.2022Frontiers in Pharmacology
Eslicarbazepine acetate add-on for drug-resistant partial epilepsy. 2021Cochrane Database of Systematic Reviews
Adjunctive eslicarbazepine acetate in pediatric patients with focal epilepsy: a systematic review and meta-analysis.2018CNS Drugs
Antiepileptic monotherapy in newly diagnosed focal epilepsy. A network meta‐analysis.2018Acta Neuroligica Scandinavica
Efficacy of antiepileptic drugs in the adjunctive treatment of refractory partial-onset seizures: meta-analysis of pivotal trials.2018Epilepsy Research
Efficacy and safety of antiepileptic drugs for refractory partial-onset epilepsy: a network meta-analysis.2018Journal of Neurology

Clinical Practice Guidelines